A study conducted on patients with HER2-overexpressed NSCLC treated with T-DM1 reported no therapeutic response in the IHC 2+ group and an ORR of 20% in the IHC 3+ group, despite a similar PFS and OS. Here, ERBB2 is linked to non-small cell lung carcinoma.